// App-Quantinova.ai

14201 : ANX-042, a Novel Natriuretic Peptide (NP), is Safe and Stimulates Cyclic Guanosine Monophosphate (cGMP) in Healthy Volunteers

Researchers

Presenter

  • Robert D Simari

Principal Investigators

  • Stephen P Youngberg

  • Celerion

  • Donna R Grogan

  • Jeffrey W Miller

  • Chorus

  • John C Burnett Jr

Medical Centers

  • Inc, Licoln, NE

  • Mayo Clinic, Rochester, MN

Locations

  • United States

Companies

  • Anexon, Inc.

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Acute decompensated heart failure

  • Orthostatic hypotension

  • Congestive heart failure

Biomarkers

  • B-type natriuretic peptide

Drug/Treatment

  • Angiotensin II

  • ANX-042

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved